ECTRIMS 2021 | Ublituximab: pending approval for relapsing MS

Ublituximab, a glycoengineered anti-CD20 monoclonal antibody, is currently under FDA review for the treatment of relapsing multiple sclerosis (MS) following reports of positive outcomes in the ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248) Phase III studies. Lawrence Steinman, MD, Stanford University, Stanford, CA, talks on how ublituximab, if approved, could benefit patients with MS. The randomized, double-blind, active-controlled ULTIMATE trials demonstrated that ublituximab was superior to teriflunomide in preventing relapses, reducing annualized relapse rates by 50-60% relative to teriflunomide. Dr Steinman comments on the convenience that ublituximab brings and why this is important given the demographics of the MS population. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.